Health Care [ 11/12 ] | Biotechnology [ 67/74 ]
NASDAQ | Common Stock
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer.
The company was founded in 2003 and is headquartered in Miami, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 31, 24 | -0.06 Decreased by -5.50% | -0.06 Decreased by -3.26% |
| Oct 30, 24 | -0.08 Decreased by -100.00% | -0.07 Decreased by -14.29% |
| Aug 6, 24 | -0.09 Decreased by -72.41% | -0.06 Decreased by -50.00% |
| Jun 14, 24 | -0.06 Decreased by -100.00% | -0.06 |
| May 1, 24 | -0.06 Decreased by -96.72% | -0.06 |
| Mar 12, 24 | -0.04 Decreased by -100.00% | - |
| Feb 20, 24 | -0.05 Decreased by -147.39% | - |
| Jan 9, 24 | -0.03 Increased by +97.90% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -62.91 M Decreased by -44.72% | Decreased by N/A% - |
| Dec 31, 24 | 0.00 Decreased by N/A% | -61.20 M Decreased by -40.78% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Increased by +100.00% | -56.25 M Decreased by -53.84% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Increased by +100.00% | -60.38 M Decreased by -65.14% | Decreased by N/A% Decreased by N/A% |
| Apr 30, 24 | N/A Decreased by N/A% | -43.47 M Decreased by -104.41% | - - |
| Mar 31, 24 | 0.00 Decreased by N/A% | -43.47 M Decreased by -104.41% | Decreased by N/A% Decreased by N/A% |
| Jan 31, 24 | -235.00 K Decreased by -200.00% | -36.57 M Decreased by -148.47% | Increased by +15.56 K% Increased by +348.47% |
| Dec 31, 23 | -235.00 K Decreased by -200.00% | -36.57 M Decreased by -148.47% | Increased by +15.56 K% Increased by +348.47% |